Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17455440 | 1.00 | UGT2B7 (0.57) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL26462904 | 0.82 | CYP1A2 (0.50) | UGT2B7CYP1A2CYP2A6TDP1 | |
| SCHEMBL26462903 | 0.82 | CYP1A2 (0.50) | UGT2B7CYP1A2CYP2A6TDP1 | |
| SCHEMBL9428117 | 0.81 | ESR1 (0.46) | UGT2B7MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL5231024 | 0.81 | UGT2B7 (0.53) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| Water SCHEMBL9839828 | 0.81 | UGT2B7 (0.68) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL11725128 | 0.80 | AKR1B1 (0.61) | UGT2B7KMT2ACYP1A2HIF1ACA1 | |
| SCHEMBL1663204 | 0.80 | UGT2B7 (0.57) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL1611816 | 0.80 | UGT2B7 (0.57) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL23255695 | 0.79 | ABCB11 (0.56) | CYP1A2TSHRCYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383838-B1 | PROCESS FOR THE CATALYTIC REVERSIBLE UNSATURATED HYDROCARBON-NITRILE INTERCONVERSION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-10-25 | — | — | EP | disclosed |
| US-10597356-B2 | Process for the catalytic reversible alkene-nitrile interconversion | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-20190031602-A1 | PROCESS FOR THE CATALYTIC REVERSIBLE ALKENE-NITRILE INTERCONVERSION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2019-01-31 | — | — | US | disclosed |
| US-9944618-B2 | Inhibiting neurotransmitter reuptake | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2017093149-A1 | Process for the Catalytic Reversible Alkene-Nitrile Interconversion | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-06-08 | — | — | WO | disclosed |
| EP-3176151-A1 | PROCESS FOR THE CATALYTIC REVERSIBLE ALKENE-NITRILE INTERCONVERSION | Studiengesellschaft Kohle mbH (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-20160024044-A1 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2016-01-28 | — | — | US | disclosed |
| WO-2014159251-A2 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-10-02 | — | — | WO | disclosed |
| US-7582764-B2 | Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids | BRANDEIS UNIVERSITY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070083049-A1 | Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids | BRANDEIS UNIVERSITY (US) | 2007-04-12 | — | — | US | disclosed |
| EP-0393940-A1 | Substituted and unsubstituted naphthalenyl-3H-1,2,3,5-oxthiadiazole 2-oxides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4910019-A | Oxathiadiazole growth promoters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
| US-4895861-A | Novel naphthalenyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| US-4833059-A | LATENT IMAGES | KABUSHIKI KAISHA TOSHIBA (JP) | 1989-05-23 | — | — | US | disclosed |
| US-4656233-A | \"Living\" polymers and chain transfer-regulated polymerization process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0186330-A1 | \"Living\" polymers and chain transfer-regulated polymerization process | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083049-A1 | Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids | ATIC, CBR3, IDH1 | UGT2B7 157/4885MEN1 3712/4885KMT2A 2237/4885 |
| US-20190031602-A1 | PROCESS FOR THE CATALYTIC REVERSIBLE ALKENE-NITRILE INTERCONVERSION | HCN2, HCN1, HCN4 | UGT2B7 943/4885MEN1 1380/4885KMT2A 1758/4885 |
| US-10597356-B2 | Process for the catalytic reversible alkene-nitrile interconversion | HCN2, HCN1, HCN4 | UGT2B7 943/4885MEN1 1380/4885KMT2A 1758/4885 |
| US-20160024044-A1 | INHIBITING NEUROTRANSMITTER REUPTAKE | SLC6A2, SLC18A2, SLC6A4 | UGT2B7 2417/4885MEN1 880/4885KMT2A 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.